UPClytics

Decisions

DateCaseDivisionActionMotionOutcomeSummary
2026-03-13UPC_CFI_722/2025Milan CDRevocation ActionRevocation meritsoutcomeName.otherThe Milan Central Division ordered disposal of Neurocrine Biosciences' revocation action (R. 360 RoP) against EP 3 784 233 because the patent had been definitively and entirely revoked by the EPO Opposition Division, rendering the revocation action devoid of purpose. Neurocrine's conditional request (disposal only if Spruce undertook not to enforce divisional patents) was held outside R. 360 RoP. Spruce (claimant/respondent) was ordered to pay 80% of maximum recoverable costs (EUR 488,000) to Neurocrine; Neurocrine was reimbursed 60% of court fees (EUR 12,000).
2026-02-18UPC_CoA_19/2026Court of AppealApplication Rop 223ProceduralProcedural onlyThe Court of Appeal (Panel 2: Kalden, Rombach, Simonsson) rejected Guardant Health's application for suspensive effect regarding the Paris Local Division's interim award of costs of EUR 400,000 ordered against Guardant following the rejection of its application for provisional measures concerning EP 3 443 066 (one of four patents originally asserted). The court found no manifest error in the CFI's interim costs award and dismissed the application. Sophia's request to set a payment deadline was also considered.
2025-08-13UPC_CoA_446/2025Court of AppealAppeal RoP220.1PI grantedThe Court of Appeal set aside the Lisbon Local Division's refusal to grant provisional measures and ordered a preliminary injunction against Zentiva Portugal prohibiting the making, offering, placing on the market or use of nintedanib products (Nintedanib Zentiva 100mg and 150mg soft capsules) for idiopathic pulmonary fibrosis in 17 UPC Contracting Member States while EP 1 830 843 remains in force. The court held that completion of national HTA/pricing/reimbursement procedures constitutes imminent infringement. Zentiva was ordered to pay EUR 199,000 as an interim award of costs. The request for an information order was denied.